10-Q · May 7, 2026
Zura Bio Limited reported a significant increase in operational losses for Q4 2026, with a net loss of $24.2 million, compared to $17.4 million in the same period last year—representing a 39% increase. The company's…
Earnings analysis · 10-Q
ZURA earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The provided excerpt is limited to Part II and does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A; therefore, revenue, margins, EPS, liquidity, and free cash flow cannot be…
Read full summary
The provided excerpt is limited to Part II and does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A; therefore, revenue, margins, EPS, liquidity, and free cash flow cannot be assessed. Controls were deemed effective as of June 30, 2026, with no material internal-control changes during the quarter. Risk factors were unchanged from the 2025 Annual Report, while no quantitative guidance was provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Effective disclosure controls
Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
-
No material control changes
The company reported no change during the quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
-
No insider trading arrangements
During the six months ended June 30, 2026, none of the company’s directors or officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement.
What to watch
-
Clinical-stage risk profile unchanged
The company states that the risks in its 2025 Annual Report remain applicable and that there have been no material changes in those risk factors. It also warns that additional risks not currently known or deemed immaterial could materially adversely affect the business, financial condition, or future results.
-
Potential litigation exposure
Although management reports no material litigation currently, it notes that litigation can create defense and settlement costs, divert management resources, and cause reputational harm, regardless of outcome.
Management's outlook
The provided 10-Q excerpt contains no quantitative revenue or EPS outlook. Management states that there have been no material changes to the risk factors in the 2025 Annual Report, but provides no updated operating guidance.
Earlier filings 4
10-K · March 19, 2026
Zura is a clinical-stage biotech focused on immune-mediated diseases, having in‑licensed three clinical-stage product candidates and advancing a bispecific IL‑17A/BAFF antibody (tibulizumab) in two Phase 2 trials. The…
10-Q · November 13, 2025
Zura reported a quarterly net loss per share of $0.21 (three months ended Sept. 30, 2025) and a nine‑month net loss of $51.5 million, driven by a stepped-up R&D spend as the company advances Phase 2 programs. Cash…
10-Q · August 14, 2025
Zura Bio reported no product revenue and a net loss of $15.993 million for the three months ended June 30, 2025 (EPS of $(0.17)), compared with a net loss of $10.329 million for Q2 2024 (EPS $(0.17)). Operating expense…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.